Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 in Malignant PEComa
NCT01690871Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Sep 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dactolisib in malignant perivascular epithelioid cell tumor, sponsored by Novartis. Planned start Sep 2012; status: withdrawn.
02
Drugs
dactolisib
03
Conditions
malignant perivascular epithelioid cell tumor
Beyond the preview
Go deeper on NCT01690871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690871.